Monitoring therapeutic monoclonal antibodies in brain tumor

被引:17
作者
Ait-Belkacem, Rima [1 ]
Berenguer, Caroline [1 ]
Villard, Claude [1 ]
Ouafik, L'Houcine [2 ]
Figarella-Branger, Dominique [1 ,3 ]
Beck, Alain [4 ]
Chinot, Olivier [1 ,3 ]
Lafitte, Daniel [1 ]
机构
[1] Aix Marseille Univ, INSERM, CRO2, UMR S 911, Marseille, France
[2] CHU Nord, APHM, Serv Transfert Oncol Biol, Marseille, France
[3] Timone Hosp, APHM, Dept Neurosurg, Marseille, France
[4] CIPF, St Julien En Genevois, France
关键词
bevacizumab; glioblastoma multiforme; MALDI imaging mass spectrometry; monoclonal antibodies; palivizumab; top down in source decay; TOP-DOWN PROTEOMICS; MASS-SPECTROMETRY; BEVACIZUMAB; PENETRATION; PROTEINS; DISCRIMINATION; CHROMATOGRAPHY; FLUOROURACIL; LEUCOVORIN; PACLITAXEL;
D O I
10.4161/mabs.34405
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Bevacizumab induces normalization of abnormal blood vessels, making them less leaky. By binding to vascular endothelial growth factor, it indirectly attacks the vascular tumor mass. The optimal delivery of targeted therapies including monoclonal antibodies or anti-angiogenesis drugs to the target tissue highly depends on the blood-brain barrier permeability. It is therefore critical to investigate how drugs effectively reach the tumor. In situ investigation of drug distribution could provide a better understanding of pharmacological agent action and optimize chemotherapies for solid tumors. We developed an imaging method coupled to protein identification using matrix-assisted laser desorption/ionization mass spectrometry. This approach monitored bevacizumab distribution within the brain structures, and especially within the tumor, without any labeling.
引用
收藏
页码:1385 / 1393
页数:9
相关论文
共 58 条
[31]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[32]   Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy [J].
Jain, RK .
SCIENCE, 2005, 307 (5706) :58-62
[33]  
Jenab-Wolcott J, 2009, EXPERT OPIN BIOL TH, V9, P507, DOI [10.1517/14712590902817817, 10.1517/14712590902817817 ]
[34]  
Lampson LA., MABS, V3, P153
[35]   N-terminal Glutamate to Pyroglutamate Conversion in Vivo for Human IgG2 Antibodies [J].
Liu, Y. Diana ;
Goetze, Andrew M. ;
Bass, Randal B. ;
Flynn, Gregory C. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (13) :11211-11217
[36]   Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours [J].
Marin, Jose J. G. ;
Romero, Marta R. ;
Blazquez, Alba G. ;
Herraez, Elisa ;
Keck, Emma ;
Briz, Oscar .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (02) :162-184
[37]   Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer [J].
Miller, Kathy ;
Wang, Molin ;
Gralow, Julie ;
Dickler, Maura ;
Cobleigh, Melody ;
Perez, Edith A. ;
Shenkier, Tamara ;
Cella, David ;
Davidson, Nancy E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26) :2666-2676
[38]   Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections [J].
Nau, Roland ;
Soergel, Fritz ;
Eiffert, Helmut .
CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (04) :858-+
[39]   Fine Mapping the Spatial Distribution and Concentration of Unlabeled Drugs within Tissue Micro-Compartments Using Imaging Mass Spectrometry [J].
Nilsson, Anna ;
Fehniger, Thomas E. ;
Gustavsson, Lena ;
Andersson, Malin ;
Kenne, Kerstin ;
Marko-Varga, Gyoergy ;
Andren, Per E. .
PLOS ONE, 2010, 5 (07)
[40]  
Noell S, 2010, BLOOD BRAIN BARRIER